Andreas Charalambous, Elise Evers, Andrew Mumford
Published on 10 June 2024
Publications
A targeted review of NICE, CADTH and ICER assessments: An evaluation of the Joint Position Statement
PICO consolidation in European HTA scoping: Examining PICO variations in oncology drugs in the context of the European Joint Clinical Assessment
Oliver Darlington, Jonathan Gibson, Daniel Hollard, Georgia Roberts, Imogen Taylor
Published on 1 June 2024
Is Carer Burden a Given When Modelling Spinal Muscular Atrophy? Examining NICE Submissions
Charlotte Ahmadu, Elise Evers, Oliver Darlington
Published on 28 November 2024
Conceptualisation and validation of a health economic model for osteogenesis imperfecta
Oliver Darlington, Tom Edmonds, Ole Henriksen, Andrew Mumford, Rafael Pinedo-Villanueva, Mark Waker, Clive Whitcher
Published on 10 June 2024
Review of indication-based pricing practice in Switzerland
Oliver Darlington, Andrew Mumford, David Ringger
Published on 1 June 2023
Increased legal certainty surrounding medicine discounting may increase Switzerland’s attractiveness as an early launch country
Andrew Mumford, David Ringger
Published on 1 June 2023
Likelihood of UK early access products to receive a positive NICE recommendation
David Ringger, Lulieth Torres
Published on 1 January 2022
The burden of adult growth hormone deficiency diagnostic tests: results of a patient experience survey in the UK
Nacima Chernai, Glenn Darley, Harry Lewis, Pat McBride, Joanne Mumford, Pauline Whittingham
Published on 21 May 2022
Estimating the true cost of weight-based chemotherapy
Janice Cheng, Tom Edmonds, Andrew Mumford, Georgia Roberts
Published on 1 December 2022
Understanding the burden of aromatic L-amino acid decarboxylase deficiency (AADCd): Results from a clinician expert survey
Paul Castellano, Jonathan Gibson, Andrew Mumford, Phillip Pearl
Published on 1 June 2023
The Cost-Effectiveness of Immunotherapies for Advanced or Recurrent Endometrial Cancer: A Systematic Review
Charlotte Ahmadu, Sarah Coyle, Oliver Darlington
Published on 28 November 2024
The economic impact and variability of managing non-tuberculous mycrobacterial lung disease in the UK healthcare setting
Craig Dixon, Andrew Mumford
Published on 10 October 2018
Association between caregiver quality of life and the care provided to adults with severe visual impairments in rare disease: A systematic review
Charlotte Ahmadu, Georgia Roberts, Joanne Mumford, Andrew Mumford, Reece Coleman
Published on 2 December 2024
Solutions to the comparator question in the absence of licensed comparators? A retrospective analysis of orphan drug and gene therapy reimbursement in EU5 markets
Bethany English, Andrew Mumford, Lorraine Munetsi, Laura Sopeña Alvarez
Published on 10 December 2020
Cost-effectiveness analysis of using hypoxic stored red blood cells to reduce the frequency of blood transfusions
Alexander Chrysos, Bethany English, Rubimbo Munetsi
Published on 10 May 2021
Novel Therapies for Neurofibromatosis Type 1-Associated Inoperable Plexiform Neurofibromas: A Systematic Literature Review
Charlotte Ahmadu, Sarah Coyle, Charlotte Webb, and Andrew Mumford
Published on 9 June 2025
Vignette-Based Economic Models in NICE Submissions: A Two-Year Review
Jonathan Gibson and Reece Coleman
Published on 21 March 2025
The impact of Leber’s hereditary optic neuropathy (LHON) on quality of life: A systematic literature review
Sarah Coyle, Jonathan Gibson, Harry Lewis, Andrew Mumford, Joanne Mumford
Published on 10 December 2023
Leber hereditary optic neuropathy: utilities and carer burden from British and Irish participants
Claire Lawrence, Emma Williams, Andrew Mumford, Steve Bojakowski, Julio Benedicto and Andrew Lloyd
Published on 16 May 2025
NICE evaluations of oncology products with EMA Conditional Marketing Authorisation
Andrew Mumford, David Ringger
Published on 1 December 2022
ATMP reimbursement: A targeted review of global HTA trends
Sarah Coyle, Harry Lewis, Andrew Mumford, Joanne Mumford
Published on 10 September 2024
Insight into the HTA process and the value of using modified Delphi
Sarah Coyle, Andrew Mumford, Joanne Mumford
Published on 10 May 2020
Delays in NICE Highly Special Technology (HST) appraisal for medicines that treat ultra-orphan conditions
David Ringger, Imogen Taylor
Published on 10 December 2023
An evaluation of the design of clinical trials conducted for rheumatoid arthritis, 2009-2022
Oliver Darlington, Myrtle Greenwood, Adelaide Shaw-Maguire, Imogen Taylor
Published on 1 June 2023
Evaluation of the updated French Autorisation d’accès précoce (AAP) Early Access Authorisation pathway
Oliver Darlington, Elise Evers, Sesh Rahim
Published on 1 June 2023
Estimating the burden of osteogenesis imperfecta on patients and healthcare payers: A health economic modelling study
Oliver Darlington, Tom Edmonds, Andrew Mumford, Ole Henriksen, Mark Waker, Clive Whitcher, Rafael Pinedo-Villaneuva
Published on 2 June 2024
Is EU orphan medicine status working? A retrospective analysis of orphan drug reimbursement in England
Sarah Coyle, Joanne Mumford, Georgia Roberts
Published on 10 December 2020
Key issues in health economic analysis in NICE Highly Specialised Technology appraisals
Harry Lewis, Andrew Mumford, David Ringger
Published on 1 June 2022
Use of UK early access data to inform NICE technology appraisals
David Ringger, Lulieth Torres
Published on 1 January 2022
An Overview of Pricing and Reimbursement Frameworks for Medicinal Products in Central and Eastern European (CEE) Countries: Mechanisms, Rules, And Managed Entry Agreements (MEAs)
Reece Coleman, Jonathan Gibson, Harry Lewis, and Andrew Mumford
Published on 9 June 2025
Challenges in rare disease treatment approval — and how to solve them
Sarah Coyle, Harry Lewis, Andrew Mumford
Published on 22 September 2023
Validation of Artificial Intelligence (AI) Tool to Identify PICO Questions for EU Joint Clinical Assessment (JCA)
Andrew Mumford, Joanne Mumford, and Georgia Roberts
Published on 9 June 2025
Virtual modified Delphi research into current and future management approaches of multiple myeloma in Sweden
Georgia Roberts, Andrew Mumford, Joanne Mumford
Published on 10 December 2020
Investigating the influence of therapy-related factors on reimbursement success: A multi-country analysis
Charlotte Ahmadu, Oliver Darlington, Elise Evers, Rachael Piper
Published on 1 June 2024
Negative reimbursement decisions and a review of methods to drive positive reimbursed status
Bethany English, Georgia Roberts, Andrew Mumford, Lorraine Munetsi
Published on 10 May 2020
Assessing the Acceptance of Single-Arm Trials in Health Technology Appraisals: A Review of NICE, CADTH, HAS, and NCPE Appraisals in 2024
Cameron Huke, Georgia Roberts, and Oliver Darlington
Published on 9 June 2025
A Review and Evaluation of Reimbursement Outcomes for Non-orphan and Orphan drugs in Ireland in 2023
Myrtle Greenwood, Sarah Jane Lyttle, Georgia Roberts, Andrew Mumford
Published on 28 November 2024
Use of Health Technology Assessments in Specialty Drug Coverage Decisions by U.S. Commercial Health Plans
Charlotte Ahmadu and Oliver Darlington
Published on 9 June 2025
Estimates on waste of breast cancer related chemotherapy drugs in the NHS (England)
Charlotte Ahmadu, Tom Edmonds, Elise Evers
Published on 1 December 2023
Is the Assumption of Treatment Waning Applied Consistently Across Canada’s Drug Agency Reimbursement Reviews? Reviewing Pharmacoeconomic Assessments of Disease Modifying Therapies for the Treatment of Multiple Sclerosis
Charlotte Ahmadu, Tom Edmonds, and Oliver Darlington
Published on 9 June 2025
Impact of Brexit-induced changes to regulatory approval on UK access to medicines
Jonathan Gibson, Alyssa Mooten, Adelaide Shaw-Maguire
Published on 1 December 2022
A Comparative Analysis of Reimbursement Outcomes for Orphan Drugs Between EU and Non-EU Countries
Sarah Jane Lyttle, Harry Lewis, Andrew Mumford
Published on 28 November 2024
A comparison of Health Technology Appraisal (HTA) timelines and requirements for orphan technologies in 10 European countries
Sarah Coyle, Tom Edmonds, Jonathan Gibson, Andrew Mumford, Joanne Mumford, Georgia Roberts
Published on 1 December 2023
A comparative analysis of the relationship between orphan drug status and reimbursement status in Ireland, Sweden, France, and Canada in 2022
Myrtle Greenwood, Sarah Jane Lyttle, Andrew Mumford, Georgia Roberts
Published on 1 June 2023
A review and evaluation of successfully reimbursed orphan and non-orphan drugs in Ireland
Myrtle Greenwood, Sarah Jane Lyttle, Andrew Mumford, Georgia Roberts
Published on 1 June 2023
Treatment adherence and quality of life in UK distal renal tubular acidosis patients
Alexander Chrysos, Scott Donald, Julia Dunnett, Joanne Mumford, Dinesha Sudusinghe, Stephen Walsh
Published on 10 May 2021
Modified Delphi research to seek consensus on dRTA disease model, treatment and management
Sarah Coyle, Scott Donald, Andrew Mumford, Joanne Mumford
Published on 1 June 2023
Emerging Treatments in Neurofibromatosis Type 1- Associated Inoperable Plexiform Neurofibromas: a Systematic Review and Recommendations
Charlotte Ahmadu, Elise Evers, Sarah Coyle, Georgia Roberts
Published on 2 December 2024
Cost-effectiveness of difelikefalin for the treatment of moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in adult patients receiving in-centre haemodialysis
Cameron Collins, Tom Edmonds, Imogen Taylor, Andrew Mumford, Oliver Darlington, Thilo Schaufler, Marco Soro, Garth Baxter
Published on 1 December 2023
A review of the use of indirect treatment comparisons to support Health Technology Assessments in Ireland
Oliver Darlington, Rachael Piper, Imogen Taylor
Published on 1 December 2023
A Global Comparative Evaluation of Health Technology Assessment Outcomes for Non-Orphan, Orphan, and Ultra-Orphan Drugs
Jane Moorhouse, Sarah Jane Lyttle, Adelaide Shaw-Maguire
Published on 28 November 2024
The long-term acceptability of COVID-19 hygiene measures for the UK population
Georgia Roberts, Bethany English, Joanne Mumford, Andrew Mumford
Published on 1 January 2022
The importance of rare disease-specific procedures in HTA processes in ensuring equitable access to orphan products as a result of EU JCA
Adelaide Shaw-Maguire, Cameron Huke, Georgia Roberts, James Wantling, Andrew Mumford
Published on 2 December 2024
Exploring the Effects of the European Union (EU) Joint Health Technology Assessment (HTA) on the Launch Sequencing of New Drugs and Identifying Opportunities to Improve the Availability of Reimbursed Medicines in Europe
Andrew Mumford, Jane Moorhouse
Published on 28 November 2024
How EAG Recommendations Affect Reimbursement Decisions in the UK: A Thematic Analysis
Elise Evers, Andreas Charalambous, Jonathan Gibson, Oliver Darlington
Published on 28 November 2024
The Cost-Effectiveness of Immunotherapies for Advanced Biliary Tract Carcinoma: A PRISMA Systematic Literature Review
Charlotte Ahmadu, Sarah Coyle, Jonathan Gibson and Tiyi Morris
Published on 21 March 2025
The global early access programme landscape and its application to cell and gene therapies
William Irvin, Andrew Mumford, Georgia Roberts, Laura Sopeña Alvarez
Published on 10 May 2021
Are There Intersections in Evidence Requirements for Health Technology Assessment Agencies across North America, Europe and the Asia-Pacific?
Charlotte Ahmadu, Sarah Coyle, and Oliver Darlington
Published on 9 June 2025
Evaluation of the UK Innovative Licensing and Access Pathway
David Ringger, Adelaide Shaw-Maguire, Imogen Taylor
Published on 1 December 2022
Health economic modelling approaches in cell and gene therapies
Harry Lewis, Andrew Mumford, David Ringger
Published on 1 June 2022
The economic impact and variability of managing distal renal tubular acidosis (dRTA) in the UK healthcare setting
Scott Donald, Catherine Matre, Andrew Mumford, Joanne Mumford
Published on 1 November 2019
Cost-effectiveness analysis of paclitaxel micellar for treatment of first relapse platinum sensitive ovarian cancer
Tom Edmonds, Bethany English, Clive Witcher, Andrew Mumford
Published on 1 December 2022
The experience and utilisation of patient reported outcomes (PROs) in Leber’s hereditary optic neuropathy (LHON): A targeted literature review
Sarah Coyle, Jonathan Gibson, Harry Lewis, Andrew Mumford, Joanne Mumford
Published on 10 December 2023
Quality of life evaluation in the UK general population Using the PedsQL questionnaire
Alexander Chysos, Iulia Dunnett, Joanne Mumford
Published on 10 May 2021
Budget Impact Analysis of Macimorelin, an Oral Growth Hormone Stimulation Test, As a Diagnostic Test for Adult Growth Hormone Deficiency (AGHD) across 5 European Countries
Bethany English, Andrew Mumford, Nacima Charnai
Published on 1 June 2022
A review and evaluation of the UK’s Innovative Licensing and Access Pathway
Myrtle Greenwood, Andrew Mumford, David Ringger, Adelaide Shaw-Maguire
Published on 1 June 2023
Thematic analysis in integrated Health Technology Assessment (HTA)
Bethany English, Andrew Mumford, Lorraine Munetsi
Published on 3 August 2021
Association Between Caregiver Quality of Life and the Care Provided to Adults With Severe Visual Impairments: A Systematic Literature Review
Charlotte Ahmadu, Georgia Roberts, Joanne Mumford, and Andrew Mumford
Published on 9 June 2025
Innovative contracting schemes for cell and gene therapies in France, Germany, Italy, Spain, and the UK
Andrew Mumford, David Ringger, Laura Sopeña Alvarez
Published on 1 January 2022
A comparison of NICE timelines for Highly Specialised Technology submissions and resubmissions
Myrtle Greenwood, Andrew Mumford, Imogen Taylor
Published on 10 June 2024
Pricing variations between early access prices and list prices in Switzerland
Oliver Darlington, Tom Edmonds, David Ringger
Published on 1 June 2023
Overview of gene therapy pricing policies and reimbursement models in the EU-5
Bethany English, Ruvimbo Munetsi, Laura Sopeña Alvarez
Published on 10 November 2020
Reasons for a negative Pharmaceutical Benefits Advisory Committee (PBAC) review in rare diseases in Australia: A comprehensive analysis
Oliver Darlington, Sarah Jane Lyttle, Andrew Mumford, Adelaide Shaw-Maguire
Published on 10 September 2024
Evaluation of NICE Severity modifiers
Janice Cheng, Cameron Collins, Andrew Mumford, Imogen Taylor
Published on 1 December 2022
Estimating the benefits of reduced fracture incidence for patients living with osteogenesis imperfecta and for healthcare payers
Oliver Darlington, Tom Edmonds, Andrew Mumford, Ole Henriksen, Mark Waker, Clive Whitcher, Rafael Pinedo-Villaneuva
Published on 1 June 2024
The Efficacy of Panitumumab Plus Chemotherapy As Initial Treatment for KRAS Wild-Type Unresectable, Metastatic Colorectal Cancer: A GRADE-Approach Systematic Review and Meta-Analysis
Charlotte Ahmadu, James Wantling, Tiyi Morris, and Oliver Darlington
Published on 9 June 2025
Assessing the definition and outcomes of innovative drugs by Health Technology Assessment bodies in England, France, and Italy (Q1 2023)
Myrtle Greenwood, Harry Lewis, Georgia Roberts, Imogen Taylor
Published on 1 December 2023
Evaluating the Impact of Benefit Reassessment Outcomes for Orphan Drugs Surpassing the Revenue Limit in Germany
Georgia Roberts, Imogen Taylor, Myrtle Greenwood, Harry Lewis
Published on 28 November 2024
The impact of differences in patient demographics on assessment of long-term cost-effectiveness in cohort level economic models
Tom Edmonds, Andrew Mumford, Oliver Darlington
Published on 10 December 2023
Gaining consensus: the challenges of living with a stoma and the impact of stoma leakage
Miriayi Aibibula, Caroline Bramwell, Gill Burry, Giovanni Cinque, Hannah Gagen, Harry Lewis, Wendy Osborne, Hazel Pixley
Published on 25 March 2022
The Guardian supplement – Rare Disease Q3 2023
Sarah Coyle, Harry Lewis, Andrew Mumford
Published on 22 September 2023
A multinational assessment of direct and indirect costs from a survey of patients with idiopathic pulmonary fibrosis (IPF)
Geoffrey Coteur, Bethany English, Jonathan Langley, Javaria Mona Khalid, Andrew Mumford, James Siddall, Mark Small
Published on 10 December 2020
Reimbursement pathways and associated timelines in European gene therapies
Andrew Mumford, Lorrain Munetsi, Laura Sopeña Alvarez
Published on 10 December 2020
